Feds commit $31 million to help Kardium manufacture its heart device in BC

By August 28, 2026
Kardium’s Globe System mapping and ablation catheter.
German chemical giant Evonik is also getting $68 million to expand its BC presence.

Burnaby, BC-based medical technology company Kardium will receive up to $31.25 million from the Government of Canada to bolster its manufacturing capabilities in the province.

“The Government of Canada’s investment is an important step in our continued growth.”

Kevin Chaplin,
Kardium

The funding was one of two new commitments announced Thursday by Innovation, Science, and Economic Development Canada through its Strategic Response Fund (SRF). Kardium, which makes a device to treat atrial fibrillation (AF), will use the funding to support a $125-million project aimed at expanding from producing 500 annual units to 30,000. The initiative is expected to create 1,000 skilled jobs in BC, and help Kardium keep its intellectual property in Canada. 

The Canadian arm of German chemical giant Evonik is also getting up to $68 million through the SRF. That money will support Evonik Canada’s $150-million push to build and operate a Nucleic Acid Competence Centre in BC to make the next generation of mRNA vaccines and therapies, which is expected to create 260 jobs. 

“Kardium is proud to be developing and manufacturing our innovative medical technology here in British Columbia,” Kardium CEO Kevin Chaplin said in a news release. “The Government of Canada’s investment is an important step in our continued growth and will help us expand our manufacturing capabilities as we bring our technology to more physicians and patients around the world.”

RELATED: Kardium closes $340 million CAD to secure regulatory approval, expand manufacturing for atrial fibrillation heart device

Kardium has been working on a heart device for AF since it was founded in 2007. AF is an irregular heartbeat disorder that affects more than 59 million people globally, putting them at a higher risk for serious complications such as heart failure. Kardium’s solution is a sophisticated catheter that maps the inside of the heart and zaps problem cells.

Kardium closed $340 million CAD last July to bring that device to market. Shortly thereafter, Kardium obtained regulatory approval from the US Food and Drug Administration to sell it, and earlier this month, Health Canada gave it the green light north of the border. According to The Globe and Mail, the 700-person company could go public as soon as the second half of 2027.

Feature image courtesy Kardium.

0 replies on “Feds commit $31 million to help Kardium manufacture its heart device in BC”